MALIGNANT HYPERTHERMIA Greg Gordon MD February 2005
MH MH Malignant Hyperthermia Objectives Things to know and do:  Participants will:  1. be able to explain the:  pathophysiology, clinical presentations, testing for and  management of malignant hyperthermia  and the MHS patient 2. be able to explain the significance of  MMR   and its management. 3. keep MH somewhere in mind as they monitor patients,  and not hesitate to give dantrolene.  4. easily correctly answer the questions in the  MH Quiz .
MH MH “ If any institution does not feel it can manage the MHS child then they should not be anaesthetising any children at all, since it is not the identified child with a nontriggering technique who will cause grief, but the undiagnosed child given a trigger.” Helen Holtby M.B.,B.S.  Director of Cardiovascular Anaesthesia  Hospital for Sick Children  Toronto, Canada  PAC List, 10 Dec 04 Malignant Hyperthermia
MH MH pharmacogenetic  hypermetabolic state of  skeletal muscle induced by inhalational anesthetics  or succinylcholine (and maybe stress/exercise)
MH MH Drugs + Genes =  Pharmacogenetic
MH MH Historical MH 1960  Denborough and Lovell 1960’s  families and pigs Gordon (?) calls it Malignant Hyperthermia 1975 dantrolene saves pigs 1979 FDA approves dantrolene 1980’s  muscle biopsy for HCCT 1990’s genetic markers/RYR1
MH MH halothane enflurane isoflurane desflurane sevoflurane
MH MH 200,000 1 (without sux)
MH MH SUX
MH MH 60,000 1 (with sux)
Incidence - Current Concepts Clinically based information:  One in 20,000 to 50,000 anesthetics  depending  on drugs, population   Molecular Genetics based information:  MH trait in 1 in 2,000-3,000 patients.  Low  penetrance
MH MH
MH MH Normal excitation-contraction coupling ACh at NMJ depolarizes sarcolemma SR (RYR) releases Ca Ca + troponin actin-myosin slide ATP hydrolyzed SR  (RYR?) re-uptake of Ca
MH MH
MH MH RYR1 ryanodine receptor Ca release channel protein (5,032 amino acids) connects SR to T-tubules Ca gate from SR chromosome 19, region 13.1
MH MH Excitation-contraction coupling in MH Defective RYR Ca release channel Too much free intracellular calcium
MH MH Too much free Ca ATP depletion lactic acidosis VO 2   way up Too much CO 2 myonecrosis/rhabdomyolysis/ ↑↑ K myoglobinemia/uria/renal failure
MH MH Diagnosis of MH tachycardia + tachypnea + ETCO 2  increasing + metabolic acidosis = MH = dantrolene IV
MH MH HCCT for MH vastus muscle 2-3 months after MH episode nontriggers no dantrolene gentle handling of muscle test within 5 hours About $6,000
Guidelines for Molecular Genetic Testing Determine MHS by HCCT If MH positive , screen for known mutation  If mutation positive,  test other family members for the mutation  If mutation negative,  cannot screen family for mutations or determine MH status
MH MH Treatment of an acute episode of MH Stop triggers 100% oxygen 10L/min Dantrolene 3 mg/kg To 10 mg/kg Rx metabolic acidosis, HCO 3 Cool, iced NS IV Rx dysrhythmias, hyperkalemia Monitor ETCO 2 , ABGs, K,  UOP, clotting tests
MH MH verapamil + dantrolene = severe hyperkalemia + myocardial depression
MH MH dantrolene
MH MH 5 year-old boy for T&A halothane induction succinylcholine jaw “stiff” for 3 minutes then relaxed
MH MH
MH MH Masseter muscle rigidity (MMR) amyotonic mytonia temporomandibular joint (TMJ) dysfunction not enough succinylcholine not enough time
MH MH The stiff jaw subclinical: normal interferes with intubation: 1-3% of children “ jaws of steel”: true MMR 50% MHS Kaplan
MH MH MMR Rosenberg cancel elective dantrolene 1-2 mg/kg observe overnight (myoglobinuria, fever,  hyperkalemia, CPK) muscle biopsy strongly considered
MH MH MMR  Gordon AVOID SUX
MH MH Malignant hyperthermia susceptible (MHS) patient A safe plan prepare to treat MH use safe drugs be happy
MH MH preop for T&A needles terrify her history of hernia repair: fever and stiff jaw went for muscle biopsy: normal  7 year-old girl
MH MH Malignant hyperthermia susceptible (MHS) patient A safe plan prepare to treat MH use safe drugs be happy
MH MH MHAUS Malignant Hyperthermia For more information MetroHealthAnesthesia.com Lesson Quiz
MH MH

Mh05

  • 1.
    MALIGNANT HYPERTHERMIA GregGordon MD February 2005
  • 2.
    MH MH MalignantHyperthermia Objectives Things to know and do: Participants will: 1. be able to explain the: pathophysiology, clinical presentations, testing for and management of malignant hyperthermia and the MHS patient 2. be able to explain the significance of MMR and its management. 3. keep MH somewhere in mind as they monitor patients, and not hesitate to give dantrolene. 4. easily correctly answer the questions in the MH Quiz .
  • 3.
    MH MH “If any institution does not feel it can manage the MHS child then they should not be anaesthetising any children at all, since it is not the identified child with a nontriggering technique who will cause grief, but the undiagnosed child given a trigger.” Helen Holtby M.B.,B.S. Director of Cardiovascular Anaesthesia Hospital for Sick Children Toronto, Canada PAC List, 10 Dec 04 Malignant Hyperthermia
  • 4.
    MH MH pharmacogenetic hypermetabolic state of skeletal muscle induced by inhalational anesthetics or succinylcholine (and maybe stress/exercise)
  • 5.
    MH MH Drugs+ Genes = Pharmacogenetic
  • 6.
    MH MH HistoricalMH 1960 Denborough and Lovell 1960’s families and pigs Gordon (?) calls it Malignant Hyperthermia 1975 dantrolene saves pigs 1979 FDA approves dantrolene 1980’s muscle biopsy for HCCT 1990’s genetic markers/RYR1
  • 7.
    MH MH halothaneenflurane isoflurane desflurane sevoflurane
  • 8.
    MH MH 200,0001 (without sux)
  • 9.
  • 10.
    MH MH 60,0001 (with sux)
  • 11.
    Incidence - CurrentConcepts Clinically based information: One in 20,000 to 50,000 anesthetics depending on drugs, population Molecular Genetics based information: MH trait in 1 in 2,000-3,000 patients. Low penetrance
  • 12.
  • 13.
    MH MH Normalexcitation-contraction coupling ACh at NMJ depolarizes sarcolemma SR (RYR) releases Ca Ca + troponin actin-myosin slide ATP hydrolyzed SR (RYR?) re-uptake of Ca
  • 14.
  • 15.
    MH MH RYR1ryanodine receptor Ca release channel protein (5,032 amino acids) connects SR to T-tubules Ca gate from SR chromosome 19, region 13.1
  • 16.
    MH MH Excitation-contractioncoupling in MH Defective RYR Ca release channel Too much free intracellular calcium
  • 17.
    MH MH Toomuch free Ca ATP depletion lactic acidosis VO 2 way up Too much CO 2 myonecrosis/rhabdomyolysis/ ↑↑ K myoglobinemia/uria/renal failure
  • 18.
    MH MH Diagnosisof MH tachycardia + tachypnea + ETCO 2 increasing + metabolic acidosis = MH = dantrolene IV
  • 19.
    MH MH HCCTfor MH vastus muscle 2-3 months after MH episode nontriggers no dantrolene gentle handling of muscle test within 5 hours About $6,000
  • 20.
    Guidelines for MolecularGenetic Testing Determine MHS by HCCT If MH positive , screen for known mutation If mutation positive, test other family members for the mutation If mutation negative, cannot screen family for mutations or determine MH status
  • 21.
    MH MH Treatmentof an acute episode of MH Stop triggers 100% oxygen 10L/min Dantrolene 3 mg/kg To 10 mg/kg Rx metabolic acidosis, HCO 3 Cool, iced NS IV Rx dysrhythmias, hyperkalemia Monitor ETCO 2 , ABGs, K, UOP, clotting tests
  • 22.
    MH MH verapamil+ dantrolene = severe hyperkalemia + myocardial depression
  • 23.
  • 24.
    MH MH 5year-old boy for T&A halothane induction succinylcholine jaw “stiff” for 3 minutes then relaxed
  • 25.
  • 26.
    MH MH Massetermuscle rigidity (MMR) amyotonic mytonia temporomandibular joint (TMJ) dysfunction not enough succinylcholine not enough time
  • 27.
    MH MH Thestiff jaw subclinical: normal interferes with intubation: 1-3% of children “ jaws of steel”: true MMR 50% MHS Kaplan
  • 28.
    MH MH MMRRosenberg cancel elective dantrolene 1-2 mg/kg observe overnight (myoglobinuria, fever, hyperkalemia, CPK) muscle biopsy strongly considered
  • 29.
    MH MH MMR Gordon AVOID SUX
  • 30.
    MH MH Malignanthyperthermia susceptible (MHS) patient A safe plan prepare to treat MH use safe drugs be happy
  • 31.
    MH MH preopfor T&A needles terrify her history of hernia repair: fever and stiff jaw went for muscle biopsy: normal 7 year-old girl
  • 32.
    MH MH Malignanthyperthermia susceptible (MHS) patient A safe plan prepare to treat MH use safe drugs be happy
  • 33.
    MH MH MHAUSMalignant Hyperthermia For more information MetroHealthAnesthesia.com Lesson Quiz
  • 34.